Back

TScan Therapeutics cuts workforce 75% to prioritize in vivo cancer therapies

Verifying
  • TScan Therapeutics announced a reorganization centered on its in vivo solid tumor pipeline.
  • 75% workforce reduction accompanied the shift, while ALLOHA-2 enrollment was paused over funding constraints.
  • TScan plans updated Cohort C data in Q4 2026 and an initial IND filing in Q3 2027.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.
TScan Therapeutics cuts workforce 75% to prioritize in vivo cancer therapies - CoinPost Terminal